0 Items
Select Page

Yellow Fever Virus

According to the World Health Organization, there are 47 countries in Africa and Central & South America that are either endemic for, or have regions that are endemic for yellow fever. A 2013 study estimated the burden of yellow fever was 84 000–170 000 severe cases and 29 000–60 000 deaths.

The Native Antigen Company offers a range of recombinant Yellow Fever virus antigens, highly specific monoclonal antibodies and donor sera from vaccine recipients to support research into YFV infection and assay development.

Yellow Fever Virus Background

Yellow fever is an acute haemorrhagic disease caused by the Yellow Fever virus (YFV), a member of the Flaviviridae family of viruses. Clinical symptoms of the disease include fever, muscle pain, nausea and vomiting. In a small percentage of patients, the liver and kidneys are affected leading to jaundice, and in some cases death. In the sylvatic cycle, the virus is transmitted to non-human primates via mosquitoes of the Haemagogus and Sabethes genera. Whereas the Aedes aegypti mosquito is responsible for the transmission of YFV to humans in urban areas. Yellow fever virus is endemic in tropical areas of Africa and Central/South America where the vector is widespread.

In the late 1930’s a safe and effective, attenuated vaccine was developed against the YFV, which confers long-term immunity. Since its introduction, the vaccine has been used successfully to immunize individuals in areas where YFV is endemic. However, vaccination coverage is sparse and lack of immunity continues to contribute to widespread outreaks.

Diagnosis of yellow fever is complicated by the fact that early symptoms of the infection can be confused with other haemorrhagic diseases including Dengue, Ebola and Zika. Differential diagnosis is therefore an important consideration in areas where other flaviviruses such as Dengue and Zika co-circulate.

References

  1. Norrby E (2007). Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J Exp Med. 204 (12):277

Yellow Fever Virus Antigens

Using our proprietary mammalian cell expression system, we have generated highly pure YFV NS1 protein in its hexameric conformation, with native glycosylation and folding. Our yellow fever NS1 proteins are ideal for use as controls and standards in ELISA, LFD and related tests for measuring patient NS1 in early infection. Our Yellow Fever virus antigen is an excellent target for developing serological assays.  

Yellow Fever Virus Antibodies

Using our recombinant YFV NS1 proteins, we have raised a panel of antibodies to NS1, all of which are highly specific and show no cross-reactivity with other flaviviral NS1 proteins, including Dengue, Zika, West Nile and Japanese Encephalitis viral proteins. These antibodies are ideal for the development of immunoassays to measure the level of YFV NS1 proteins.

Yellow Fever Virus Donor Sera

Donor sera from a controlled group of Yellow Fever vaccine recipients are available for use as controls in IVD assays, and for studies into vaccine responses

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

We recently teamed-up with Virology Research Services (VRS) who tested a large panel of our viral antibodies in immunofluorescence applications. This work was funded by the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) through the...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

What should you call your favourite virus?

The International Committee on Taxonomy of Viruses (ICTV) meet regularly to ensure the taxonomy of viruses is kept logical and up-to-date in the face of an ever-increasing number of new viruses and genome sequences; discussed in here in Nature. This sometimes results...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

3 + 12 =

Live Customer Feedback